Journal of Nephrology

, Volume 31, Issue 1, pp 1–13 | Cite as

Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease: a position statement by the Spanish association of the liver and the kidney

  • Sami Aoufi-Rabih
  • Rebeca García-Agudo
  • María-Carlota Londoño
  • María-Dolores Fraga-Fuentes
  • Guillermina Barril-Cuadrado
  • On behalf on the Spanish Association of the Liver and the Kidney (AEHR)
Position Papers and Guidelines


Hepatitis C virus (HCV) infection is one of the main causes of liver cirrhosis worldwide. The long-term impact of HCV infection is highly variable, ranging from minimal histological changes to extensive fibrosis with hepatocellular carcinoma. The development of HCV drugs has increased dramatically in recent years, even in special populations such as chronic kidney disease patients. Classical treatment of chronic hepatitis C was based on the administration of interferon and ribavirin for 24–48 weeks, which was associated with a poor viral response and a high rate of side effects, especially in patients with a lower estimated glomerular filtration rate. The current high availability of the new direct-acting antivirals renders the classification of these agents for this special population necessary. The Spanish Association of the Liver and the Kidney has produced a position statement on the treatment of HCV infection in chronic kidney disease patients since the evidence to guide this treatment is scant and what evidence does exist is weak. The recommendations are based on the results of clinical trials and controlled studies conducted to date, with data published hitherto by the authors of these studies. Since the indications for treatment have been evaluated by other societies or are dependent on internal clinical protocols, the main goal of this position statement is to assist in decision-making when choosing a therapeutic option.


Hepatitis C virus Chronic kidney disease Cirrhosis Direct-acting antiviral 



Beatriz Proy Vega contributed to the investigation of this work.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human participants or animals

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

For this type of study formal consent is not required.


  1. 1.
    Fisell RB, Bragg-Gresaham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA et al (2004) Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 65(6):2335–2342. doi: 10.1111/j.1523-1755.2004.00649.x CrossRefGoogle Scholar
  2. 2.
    Sivapalasingam S, Malak SF, Sullivan JF, Lorch J, Sepkowitz KA (2002) High prevalence of hepatitis C infection among patients receiving hemodialysis at an urban dialysis center. Infect Control Hosp Epidemiol 23(6):319–324. doi: 10.1086/502058 CrossRefPubMedGoogle Scholar
  3. 3.
    Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ (2005) National surveillance of dialysis associated diseases in the US, 2002. Semin Dial 18(1):52–61. doi: 10.1111/j.1525-139X.2005.18108.x CrossRefPubMedGoogle Scholar
  4. 4.
    Espinosa M, Martín-Malo A, Ojeda R, Santamara R, Soriano S, Aguera M et al (2004) Marked reduction in the prevalence of hepatitis C virus infection in hemodialysis patients: causes and consequences. Am J Kidney Dis 43(4):685–689 PMID: 15042545CrossRefPubMedGoogle Scholar
  5. 5.
    Jadoul M, Poignet JL, Geddes C, Locatelli F, Medin C, Krajewska M, HCV Collaborative Group et al (2004) The changing epidemiology of hepatitis C virus (HCV) infection in hemodialysis: European multicenter study. Nephrol Dial Transplant 19(4):904–909CrossRefPubMedGoogle Scholar
  6. 6.
    Pereira BJ, Natov SN, Bouthot BA, Murthy BV, Ruthazer R, Schmid CH et al (1998) Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 53(5):1374–1381. doi: 10.1046/j.1523-1755.1998.00883.x CrossRefPubMedGoogle Scholar
  7. 7.
    García-Agudo R, Aoufi-Rabih S, Barril-Cuadrado G, Grupo de Virus en Diálisis de la Sociedad Española de Nefrología (2013) SHECTS multi-center Spanish study: liver situation of patients with chronic hepatitis from HCV on renal replacement therapy with hemodialysis. Nefrologia 33(2):188–195. doi: 10.3265/Nefrologia.pre2012.Nov.11668 PubMedGoogle Scholar
  8. 8.
    Hanafusa T, Ichikawa Y, Kishikawa H, Kyo M, Fukunishi T, Kokado Y et al (1998) Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 66(4):471–476CrossRefPubMedGoogle Scholar
  9. 9.
    Vosnides GG (1997) Hepatitis C in renal transplantation. Kidney Int 52(3):843–861CrossRefPubMedGoogle Scholar
  10. 10.
    Fabrizi F, Dixit V, Messa P (2012) Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat 19(9):601–607. doi: 10.1111/j.1365-2893.2012.01633.x CrossRefPubMedGoogle Scholar
  11. 11.
    Maisonneuve P, Agodoa L, Gellert R, Stewar JH, Buccianti G, Lowenfels AB et al (1999) Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 354(9173):93–99CrossRefPubMedGoogle Scholar
  12. 12.
    Morales JM, Domínguez-Gil B, Sanz-Guajardo D, Fernández J, Escuin F (2004) The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure. Nephrol Dial Transpl 19 Suppl 3:iii72–iii76. doi: 10.1093/ndt/gfh1020 Google Scholar
  13. 13.
    Hestin D, Guillermin F, Castin N, Le Faou A, Champigneulles J, Kessler M (1998) Pretransplant hepatitis C virus infection: a predictor of proteinuria after renal transplantation. Transplantation 65(5):741–744CrossRefPubMedGoogle Scholar
  14. 14.
    Bloom RD, Rao V, Weng F, Grossman RA, Cohen D, Mange KC (2002) Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 13(5):1374–1380CrossRefPubMedGoogle Scholar
  15. 15.
    Kamar N, Mariat C, Delahousse M, Dantal J, al. Najjar A, Cassuto E, Diapason Study Group, et al (2007) Diabetes mellitus after kidney transplantation: a French multicenter observational study. Nephrol Dial Transpl 22(7):1986–1993. doi: 10.1093/ndt/gfm011 CrossRefGoogle Scholar
  16. 16.
    Fabrizi F, Martin P, Dixit V, Bunnapradist S, Kanwal F, Dulai G (2005) Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transpl 5(19):2433–2440. doi: 10.1093/ndt/gfm011 CrossRefGoogle Scholar
  17. 17.
    Roth D, Cirocco R, Zucker K, Ruiz P, Viciana A, Burke G et al (1995) De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. Transplantation 59(12):59:1676–1682CrossRefPubMedGoogle Scholar
  18. 18.
    Floege J (2003) Recurrent glomerulonephritis following renal transplantation: an update. Nephrol Dial Transpl 18(7):1260–1265CrossRefGoogle Scholar
  19. 19.
    Choy BY, Chan TM, Lai KN (2006) Recurrent glomerulonephritis after kidney transplantation. Am J Transpl 6(11):2535–2542. doi: 10.1111/j.1600-6143.2006.01502.x CrossRefGoogle Scholar
  20. 20.
    Kamar N, Izopet J, Alric L, Guilbeaud-Frugier C, Rostaing L (2008) Hepatitis C virus-related kidney disease: an overview. Clin Nephrol 69(3):149–160CrossRefPubMedGoogle Scholar
  21. 21.
    Kidney Disease: Improving Global Outcomes (KDIGO) (2008) Clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int 73(Suppl 109):S53–S68. doi: 10.1038/ki.2008.81 Google Scholar
  22. 22.
    Kamar N, Ribes D, Izopet J, Rostaing L (2006) Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant. Transplantation 82(7):853–856. doi: 10.1097/ CrossRefPubMedGoogle Scholar
  23. 23.
    Toth CM, Pascual M, Chung RT, Graeme-Cook F, Dienstag JL, Bhan AK et al (1998) Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy. Transplantation 66(9):1254–1258CrossRefPubMedGoogle Scholar
  24. 24.
    Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW et al (2014) Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 59(4):1293–1302. doi: 10.1002/hep.26892 CrossRefPubMedGoogle Scholar
  25. 25.
    Molnar MZ, Alhourani HM, Wall BM, Lu JL, Streja E, Kalantar-Zadeh K et al (2015) Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology 61(5):1495–1502. doi: 10.1002/hep.27664 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    García García M, Oppenheimer F, Valencia J (2006) Valoración y seguimiento de inclusión en lista de espera para trasplante renal. Nefrologia 26 Suppl 8:60–69PubMedGoogle Scholar
  27. 27.
    Campistol JM, Darnell A (2014) Trasplante renal: manejo clínico. In: Protocolos del Servicio de Nefrología y Trasplante renal. Hospital Clínic de Barcelona. Euromedici, BadalonaGoogle Scholar
  28. 28.
    Alonso Gil M (2016) Proceso asistencial integrado. Tratamiento sustitutivo de la IRC: diálisis y trasplante renal. Seville: Consejería de Salud, Junta de Andalucía.
  29. 29.
    Fabrizi F, Dixit V, Martin P, Messa P (2011) Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials. J Viral Hepat 18(7):e263-e269. doi: 10.1111/j.1365-2893.2010.01405.x CrossRefGoogle Scholar
  30. 30.
    European Association for Study of the Liver (2015) EASL recommendations on treatment of hepatitis C 2015. J Hepatol;63(1):199–236. doi: 10.1016/j.jhep.2015.03.025 CrossRefGoogle Scholar
  31. 31.
    Kowdley KV, Gordon SC (2014) Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370(20):1879–1888. doi: 10.1056/NEJMoa1402355 CrossRefPubMedGoogle Scholar
  32. 32.
    Pockros PJ, Rajender Reddy K, Mantry PS, Cohen E, Bennett M, Sulkowski MS et al (2016) Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology 150(7):1590–1598. doi: 10.1053/j.gastro.2016.02.078 CrossRefPubMedGoogle Scholar
  33. 33.
    Poordad F, Herode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K et al (2014) ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 370(21):1973–1982. doi: 10.1056/NEJMoa1402869 CrossRefPubMedGoogle Scholar
  34. 34.
    Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H Jr et al (2015) Grazoprevir plus elbasvir in treatment-naïve and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 386(10003):1537–1545. doi: 10.1016/S0140-6736(15)00349-9 CrossRefPubMedGoogle Scholar
  35. 35.
    Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, ASTRAL-4 Investigators et al (2015) Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373(27):2618–2628. doi: 10.1056/NEJMoa1512614 CrossRefPubMedGoogle Scholar
  36. 36.
    AASLD/IDSA HCV Guidance Panel (2015) Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62(3):932–954. doi: 10.1002/hep.27950 CrossRefGoogle Scholar
  37. 37.
    Kwo P, Gane EJ, Peng CY, Pearlman B, Vierling JM, Serfaty L et al (2017) Effectiveness of Elbasvir and Grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology 152(1):164–175. doi: 10.1053/j.gastro.2016.09.045 CrossRefPubMedGoogle Scholar
  38. 38.
    Munoz-Gomez R, Rincon D, Ahumada A, Hernandez E, Devesa M, Izquierdo S et al (2017) Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus infection in patients with severe renal impairment: a multicenter experience. J Viral Hepatol 24(6):464–471. doi: 10.1111/jvh.12664 CrossRefGoogle Scholar
  39. 39.
    Welzel TM, Hinrichsen H, Sarrazin C, Buggisch P, Baumgarten A, Christensen S et al (2017) Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry. J Viral Hepat. doi: 10.1111/jvh.12708 (Epub ahead of print) PubMedGoogle Scholar
  40. 40.
    Ponziani FR, Siciliano M, Lionetti R, Pasquazzi C, Gianserra L, D’Offizi G et al (2017) Effectiveness of paritaprevir/ritonavir/ombitasvir/dasabuvir in hemodialysis patients with hepatitis C virus infection and advanced liver fibrosis: case reports. Am J Kidney Dis 70(2):297–300. doi: 10.1053/j.ajkd.2017.01.037 CrossRefPubMedGoogle Scholar
  41. 41.
    Sato K, Hosonuma K, Yamazaki Y, Kobayashi T, Takakusagi S, Horiguchi N et al (2017) Combination therapy with ombitasvir/paritaprevir/ritonavir for dialysis patients infected with hepatitis C virus: a prospective multi-institutional study. Tohoku J Exp Med 241(1):45–53. doi: 10.1620/tjem.241.45 CrossRefPubMedGoogle Scholar
  42. 42.
    Saxena V, Koraishy FM, Sise M, Lim JK, Schmidt M, Chung RT (2016) Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int 36(6):807–816. doi: 10.1111/liv.13102 CrossRefPubMedGoogle Scholar
  43. 43.
    Desnoyer A, Pospai D, Patric Le M, Gervais A, Heurgué-Berlot A, Laradi A et al (2016) Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol 65(1):40–47. doi: 10.1016/j.jhep.2016.02.044 CrossRefPubMedGoogle Scholar
  44. 44.
    Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, ASTRAL-1 Investigators et al (2015) Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373(27):2599–2607. doi: 10.1056/NEJMoa1512610 CrossRefPubMedGoogle Scholar
  45. 45.
    Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, ASTRAL-2 Investigators, ASTRAL-3 Investigators et al (2015) Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373(27):2608–2617. doi: 10.1056/NEJMoa1512612 CrossRefPubMedGoogle Scholar
  46. 46.
    Mangia A, Arleo A, Copetti M, Miscio M, Piazzolla V, Santoro R et al (2016) The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin. Liver Int 36(7):971–976. doi: 10.1111/liv.13069 CrossRefPubMedGoogle Scholar
  47. 47.
    Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, VALENCE Investigators et al (2014) Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 370(21):1993–2001. doi: 10.1056/NEJMoa1316145 CrossRefPubMedGoogle Scholar
  48. 48.
    Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, POSITRON Study, FUSION Study et al (2013) Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368(20):1867–1877. doi: 10.1056/NEJMoa1214854 CrossRefPubMedGoogle Scholar
  49. 49.
    Welzel TM, Nelson DR, Morelli G, Di Bisceglie A, Reddy RK, Kuo A HCV-TARGET Study Group et al (2016) Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut 0:1–9. doi: 10.1136/gutjnl-2016-311609] Google Scholar
  50. 50.
    Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, ALLY-3 Study Team et al (2015) All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 61(4);1127–1135. doi: 10.1002/hep.27726 CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S et al (2016) Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology 63(5):1430–1441. doi: 10.1002/hep.28473 CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Hézode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K et al (2015) Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naïve and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 385(9986):2502–2509. doi: 10.1016/S0140-6736(15)60159-3 CrossRefPubMedGoogle Scholar
  53. 53.
    Kohli A, Kapoor R, Sims Z, Nelson A, Sidharthan S, Lam B et al (2015) Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-center, open-label phase 2a cohort study. Lancet Infect Dis 15(9):1049–1054. doi: 10.1016/S1473-3099(15)00157-7 CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Abergel A, Asselah T, Metivier S, Kersey K, Jiang D, Mo H, Pang PS, Samuel D, Loustaud-Ratti V (2016) Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicenter, single-arm, phase 2 study. Lancet Infect Dis 16(4):459–464. doi: 10.1016/S1473-3099(15)00529-0 CrossRefPubMedGoogle Scholar
  55. 55.
    Gane EJ, Hyland RH, An D, Svarovskaia E, Pang PS, Brainard D (2015) Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology 149(6):1454–1461. doi: 10.1053/j.gastro.2015.07.063 CrossRefPubMedGoogle Scholar
  56. 56.
    Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Bräu N, Brown A et al. (2016) EXPEDITION-4: Efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in patients with renal impairment and chronic hepatitis C virus genotype 1–6 infection. AASLD 2016 Nov 11–15 Boston, MAGoogle Scholar
  57. 57.
    Talavera Pons S, Boyer A, Lamblin G, Chennell P, Châtenet FT, Nicolas C et al (2016) Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C. Br J Clin Pharmacol 83(2):269–293. doi: 10.1111/bcp.13095 CrossRefPubMedGoogle Scholar
  58. 58.
    Bradi P, Dutta S, Coakley E, Cohen D, Ding B, Podsadecki T et al (2015) Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transpl 15(5):1313–1322. doi: 10.1111/ajt.13111 CrossRefGoogle Scholar
  59. 59.
    HEP Drug interactions. University of Liverpool.
  60. 60.
    Ouwerkerk-Mahadevan S, Vanwelkenhuysen I, Peeters M, Simonts M, Ilsbroux I, Simion A et al (2015) P0834: Significant drug–drug interaction between simeprevir and cyclosporine but not tacrolimus in patients with recurrent chronic HCV infection after orthotopic liver transplantation: the Saturn study. J Hepatol 62(Suppl 2):S650CrossRefGoogle Scholar
  61. 61.
    Colombo M, Aghemo A, Liu H, Zhang J, Dvory-Sobol H, Hyland R et al (2017) Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial. Ann Intern Med 166(2):109–117. doi: 10.7326/M16-1205 CrossRefPubMedGoogle Scholar
  62. 62.
    Kamar N, Marion O, Rostaing L, Cointault O, Ribes D, Lavayssière L et al (2016) Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation. Am J Transpl 16(5):1474–1479. doi: 10.1111/ajt.13518 CrossRefGoogle Scholar
  63. 63.
    Beinhardt S, al. Zoairy R, Ferenci P, Kozbial K, Freissmuth C, Stern R et al (2016) DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and post-kidney transplantation setting. Transpl Int 29(9):999–1007. doi: 10.1111/tri.12799 CrossRefPubMedGoogle Scholar
  64. 64.
    Sawinski D, Kaur N, Ajeti A, Trofe-Clark J, Lim M, Bleicher M et al (2016) Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transpl 16:1588–1595. doi: 10.1111/ajt.13620 CrossRefGoogle Scholar
  65. 65.
    Lin MV, Sise ME, Pavlakis M, Amundsen BM, Chute D, Rutherford AE et al (2016) Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic hepatitis C virus infection. PLoS One 11(7):e0158431. doi: 10.1371/journal.pone.0158431 CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I).
  67. 67.
    Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R Jr et al (2014) An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 371(25):2375–2382. doi: 10.1056/NEJMoa1408921 CrossRefPubMedGoogle Scholar

Copyright information

© Italian Society of Nephrology 2017

Authors and Affiliations

  • Sami Aoufi-Rabih
    • 1
  • Rebeca García-Agudo
    • 2
  • María-Carlota Londoño
    • 3
  • María-Dolores Fraga-Fuentes
    • 4
  • Guillermina Barril-Cuadrado
    • 5
  • On behalf on the Spanish Association of the Liver and the Kidney (AEHR)
  1. 1.Hepatorenal Unit, Department of Gastroenterology and HepatologyHospital General La Mancha-CentroAlcázar de San JuanSpain
  2. 2.Hepatorenal Unit, Department of NephrologyHospital General La Mancha-CentroAlcázar de San JuanSpain
  3. 3.Hepatology UnitHospital ClínicBarcelonaSpain
  4. 4.Department of PharmacyHospital General La Mancha-CentroAlcázar de San JuanSpain
  5. 5.Department of NephrologyHospital Universitario La PrincesaMadridSpain

Personalised recommendations